Amydis Diagnostics, Inc.
3210 Merryfield Row
About Amydis Diagnostics, Inc.Amydis Diagnostics was founded to address the urgent medical and clinical need for more sensitive and specific diagnostic testing for Alzheimer’s disease. By significantly improving the effectiveness, accessibility, and ease of testing, our unique technology has the potential to help physicians detect Alzheimer’s disease at its earliest stages. The power of knowing will enable patients and physicians to make the right decisions and change the lives of those impacted by the disease.
Founder and CEO: Stella Sarraf
Founder and CSO: Jerry Yang
CTO: Richard D’Souza
CBO: David H. Crean
CFO: Dan Albosta
5 articles with Amydis Diagnostics, Inc.
5/3/2021Although clinical trial news related to COVID-19 was slow last week, there’s quite a bit of news on studies for other indications.
Amydis Announces Successful Completion of Pre-IND Meeting with the FDA for the Development of a First-in-Class Retinal Tracer for the Diagnosis of Alpha-synucleinopathies
Amydis Inc., a leading ocular tracer biotechnology company with a broad portfolio of diagnostic candidates for detection of neurodegenerative diseases in the eye, announced completion of pre-IND interaction with the U.S. Food and Drug Administration regarding the current development plan for a small-molecule retinal tracer for the diagnosis of α-synucleinopathies.
Amydis Diagnostics, Inc. Adds Veteran Drug Development Executive And Chief Medical Officer To Management Team
Amydis Diagnostics, Inc. Awarded NIH Grant To Further Investigate Innovative Technology For Early Detection Of Alzheimer’s Disease